HIV treatment add-on antibodies during early infection
Part of Immune system & allergy, Infections clinical trials.
This study tests whether adding two antibody medicines to standard HIV treatment helps people control HIV better after stopping treatment. It focuses on people with recently diagnosed (“primary”) HIV infection, aiming to improve long-term control after ART is interrupted.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of primary (recent) HIV infection
- You are age 18 to 70
- You can use reliable birth control during the study, and you are not pregnant or breastfeeding
- You can and are willing to follow trial rules, including traveling for antibody infusions and stopping HIV medicine as the study requires
- You are able to get COVID-19 vaccination if asked and consent to the study in writing
- Blood/health tests must be safe for treatment (no major liver/kidney problems, and certain clotting levels must be high enough)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether adding long-acting HIV antibodies to standard HIV treatment (ART) can help control HIV in people who started ART soon after getting infected. It also checks how safe the antibody treatment is and how well it works over time.
This trial tests whether a combination of powerful antibodies (bNAbs) can help control HIV after stopping standard HIV treatment. Participants will pause their daily HIV medications while receiving these antibodies, and doctors will closely monitor their immune system and virus levels. It's for people who are already well-controlled on HIV treatment and have participated in a specific earlier study.
This study tests whether a combination of two lab-made antibodies plus an immunotherapy drug can help control HIV without daily antiretroviral pills. If successful, it might allow a safe break from your current HIV medications while keeping the virus under control.
This study tests whether giving a special antibody treatment to babies living with HIV, shortly after birth, can help their immune system fight the virus better. It aims to improve their long-term health.
This trial tests a new antibody medication given as a shot to babies with HIV. It aims to help control the virus and may be an option for infants who are newly diagnosed or starting treatment.
This trial tests whether giving two powerful HIV-fighting antibodies (called broadly neutralizing monoclonal antibodies) along with starting standard HIV medications soon after infection can help control the virus without needing daily pills. If successful, it might allow people to take a 'treatment pause' while keeping their immune system healthy.
Hear when a new HIV/AIDS and Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.